A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Darolutamide in Addition to Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Men With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
收藏DataCite Commons2025-12-18 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00012443/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of the study is to assess the efficacy and safety of darolutamide in combination with standard androgen deprivation therapy (ADT) in patients with metastatic hormone sensitive prostate cancer.
提供机构：
Vivli
创建时间：
2025-12-18
